Ha­le­on ups full-year guid­ance af­ter rocky spin­off from GSK

Af­ter get­ting off to a rather rocky start in Ju­ly, GSK’s con­sumer health spin­off Ha­le­on is up­ping its full-year sales guid­ance on the heels of what CEO Bri­an Mc­Na­ma­ra called a “strong quar­ter of growth.”

The spin­out is now ex­pect­ing an 8% to 8.5% growth in rev­enue this year, as op­posed to a pre­vi­ous­ly an­tic­i­pat­ed 6% to 8%. That’s due to a rough­ly 12% uptick in oral health sales and sol­id res­pi­ra­to­ry fig­ures as we en­ter cold and flu — and like­ly Covid — sea­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER